Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Issue 4 (19th February 2021)

• Record Type: Journal Article
• Authors: Yuan, Juanjuan; Cai, Ting; Zheng, Xiaojun; Ren, Yangzi; Qi, Jingwen; Lu, Xiaofei; Chen, Huihui; Lin, Huizhen; Chen, Zijie; Liu, Mengnan; He, Shangwen; Chen, Qijun; Feng, Siyang; Wu, Yingjun; Zhang, Zhenhai; Ding, Yanqing; Yang, Wei
• Is Part Of: Protein & cell. Volume 12:Issue 4(2021)
• Page Start: 240
• Page End: 260
• Publication Date: 2021-02-19
• Subjects: LDLR -- PCSK9 -- TCR -- CD8+ T cells -- tumor microenvironment -- cancer immunotherapy; Proteins -- Periodicals; Cells -- Periodicals; Cytology -- Periodicals; 572.6
• DOI: 10.1007/s13238-021-00821-2
• Languages: English
• ISSNs: 1674-800X

Abstract

Abstract: Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR), which has been previously identified as a transporter for cholesterol, plays a pivotal role in regulating CD8 + T cell antitumor activity. Besides the involvement of cholesterol uptake which is mediated by LDLR in T cell priming and clonal expansion, we also found a non-canonical function of LDLR in CD8 + T cells: LDLR interacts with the T-cell receptor (TCR) complex and regulates TCR recycling and signaling, thus facilitating the effector function of cytotoxic T-lymphocytes (CTLs). Furthermore, we found that the tumor microenvironment (TME) downregulates CD8 + T cell LDLR level and TCR signaling via tumor cell-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) which binds to LDLR and prevents the recycling of LDLR and TCR to the plasma membrane thus inhibits the effector function of CTLs. Moreover, genetic deletion or pharmacological inhibition of PCSK9 in tumor cells can enhance the antitumor activity of CD8 + T cells by alleviating the suppressive effect on CD8 + T cells and consequently inhibit tumor progression. While previously established as a hypercholesterolemia target, this study highlights PCSK9/LDLR as a potential target for cancer immunotherapy as well.